Study shows pharma is by no means pocketing all the profits from drug sales

10 January 2022

More than half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders in 2020, according to a new analysis from the Berkeley Research Group (BRG).

This research has been cited by Pharmaceutical Research and Manufacturers of America (PhRMA) to illuminate issues that exist throughout the USA’s health care system and why holistic, patient-centered solutions are needed to make medicines more affordable for patients.

The analysis looks at all spending on brand medicines at the pharmacy or paid on a claim to a health care provider.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK